No Data
No Data
Earnings Preview: MDGL to Report Financial Results Pre-market on May 01
12 Health Care Stocks Moving In Friday's After-Market Session
Evercore Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $392
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Pfizer (PFE) and Madrigal Pharmaceuticals (MDGL)
JMP Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $443
Express News | JMP Securities Reiterates Market Outperform on Madrigal Pharmaceuticals, Maintains $443 Price Target